VA
OCUL icon

VR Adviser’s Ocular Therapeutix OCUL Stock Holding History

VR Adviser’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Hold
10,346,926
– – 3.08% 6
2026
Q1 		$87.6M Buy
10,346,926
+3,031,379
+41% +$28.9M 3.27% 8
2025
Q4 		$88.8M Sell
7,315,547
-5,845,915
-44% -$71M 4.39% 6
2025
Q3 		$154M Buy
13,161,462
+399,000
+3% +$4.77M 8.66% 3
2025
Q2 		$118M Hold
12,762,462
– – 8.88% 2
2025
Q1 		$93.5M Hold
12,762,462
– – 7.96% 3
2024
Q4 		$109M Hold
12,762,462
– – 7.48% 2
2024
Q3 		$111M Hold
12,762,462
– – 5.82% 2
2024
Q2 		$87.3M Hold
12,762,462
– – 5.56% 4
2024
Q1 		$116M Buy
12,762,462
+4,986,702
+64% +$35.4M 5.52% 3
2023
Q4 		$34.7M Buy
+7,775,760
New +$23M 2.38% 11

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VR Adviser's OCUL Position: Q2 2026 in Review

VR Adviser held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 10,346,926 shares worth $102M. The position accounts for 3.08% of the portfolio, ranked #6.

VR Adviser first reported a position in OCUL in Q4 2023 and has held it in 11 quarters since. The position peaked at $154M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • VR Adviser held 10,346,926 shares of Ocular Therapeutix worth $102M as of Q2 2026.
  • VR Adviser left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up 3.08% of VR Adviser's portfolio in Q2 2026, its #6 holding.
  • VR Adviser first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 11 quarters since.
  • VR Adviser's Ocular Therapeutix position peaked at $154M in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.